Antonio Cristiano1*, Raffaele Palmieri1*, Emiliano Fabiani1,2, Tiziana Ottone1, Mariadomenica Divona1, Arianna Savi1, Francesco Buccisano1, Luca Maurillo1, Corrado Tarella3, William Arcese1 and Maria Teresa Voso1.
1 Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, Italy.
2 UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
3 European Institute of Oncology (IEO) and University of Milan, Milan, Italy.
* The first two authors equally contributed to this work.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
addition of Venetoclax (VEN) to Hypomethylating agents (HMAs)
significantly improves the probability of complete remission and
prolongs survival in patients with Acute Myeloid Leukemia (AML) when
compared to HMA alone. However, the mutated clone composition may
impact the probability of response and its duration.
1. Clonal evolution of a t-CMML to AML, and during VEN/AZA combination treatment.